The 50-day moving average for CERS moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CERS as a result. In 93 of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for CERS turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 39 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for CERS entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CERS's RSI Oscillator exited the oversold zone, 25 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +1.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where CERS advanced for three days, in 167 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
CERS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.813) is normal, around the industry mean (4.142). P/E Ratio (-67.333) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.219) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. CERS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CERS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
FLGT saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 75 similar instances where the indicator turned positive. In 56 of the 75 cases, the stock moved higher in the following days. The odds of a move higher are at 75%.
The Moving Average Convergence Divergence (MACD) for FLGT just turned positive on November 06, 2026. Looking at past instances where FLGT's MACD turned positive, the stock continued to rise in 30 of 48 cases over the following month. The odds of a continued upward trend are 62%.
FLGT moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for FLGT crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +40.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where FLGT advanced for three days, in 188 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FLGT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
FLGT broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for FLGT entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.652) is normal, around the industry mean (67.298). P/E Ratio (-8.389) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.013) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. FLGT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FLGT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
CERS | FLGT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 28 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 36 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 93 | |
PRICE GROWTH RATING 1..100 | 63 | 37 | |
P/E GROWTH RATING 1..100 | 13 | 73 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CERS's Valuation (9) in the Medical Specialties industry is in the same range as FLGT (36) in the Medical Or Nursing Services industry. This means that CERS’s stock grew similarly to FLGT’s over the last 12 months.
CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as FLGT (100) in the Medical Or Nursing Services industry. This means that CERS’s stock grew similarly to FLGT’s over the last 12 months.
FLGT's SMR Rating (93) in the Medical Or Nursing Services industry is in the same range as CERS (94) in the Medical Specialties industry. This means that FLGT’s stock grew similarly to CERS’s over the last 12 months.
FLGT's Price Growth Rating (37) in the Medical Or Nursing Services industry is in the same range as CERS (63) in the Medical Specialties industry. This means that FLGT’s stock grew similarly to CERS’s over the last 12 months.
CERS's P/E Growth Rating (13) in the Medical Specialties industry is somewhat better than the same rating for FLGT (73) in the Medical Or Nursing Services industry. This means that CERS’s stock grew somewhat faster than FLGT’s over the last 12 months.
| CERS | FLGT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 81% | 1 day ago 59% |
| Stochastic ODDS (%) | 1 day ago 86% | 1 day ago 76% |
| Momentum ODDS (%) | 1 day ago 89% | 1 day ago 75% |
| MACD ODDS (%) | 1 day ago 89% | 1 day ago 63% |
| TrendWeek ODDS (%) | 1 day ago 85% | 1 day ago 69% |
| TrendMonth ODDS (%) | 1 day ago 83% | 1 day ago 69% |
| Advances ODDS (%) | 14 days ago 75% | 3 days ago 68% |
| Declines ODDS (%) | 6 days ago 84% | 1 day ago 77% |
| BollingerBands ODDS (%) | 1 day ago 89% | 1 day ago 73% |
| Aroon ODDS (%) | 1 day ago 84% | 1 day ago 82% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CERS’s FA Score shows that 2 FA rating(s) are green while FLGT’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CERS’s TA Score shows that 4 TA indicator(s) are bullish while FLGT’s TA Score has 5 bullish TA indicator(s).
CERS (@Medical/Nursing Services) experienced а -16.67% price change this week, while FLGT (@Medical Specialties) price change was +33.09% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.92%. For the same industry, the average monthly price growth was -5.08%, and the average quarterly price growth was +38.31%.
CERS is expected to report earnings on Feb 25, 2027.
FLGT is expected to report earnings on Feb 26, 2027.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-4.92% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
A.I.dvisor indicates that over the last year, CERS has been loosely correlated with ICUI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To CERS | 1D Price Change % | ||
|---|---|---|---|---|
| CERS | 100% | +8.72% | ||
| ICUI - CERS | 46% Loosely correlated | -2.11% | ||
| UTMD - CERS | 45% Loosely correlated | +0.23% | ||
| RVTY - CERS | 44% Loosely correlated | -0.53% | ||
| ATRC - CERS | 43% Loosely correlated | +2.26% | ||
| DHR - CERS | 43% Loosely correlated | -0.34% | ||
More | ||||
A.I.dvisor indicates that over the last year, FLGT has been loosely correlated with CERS. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if FLGT jumps, then CERS could also see price increases.
| Ticker / NAME | Correlation To FLGT | 1D Price Change % | ||
|---|---|---|---|---|
| FLGT | 100% | -0.31% | ||
| CERS - FLGT | 40% Loosely correlated | +8.72% | ||
| BIO - FLGT | 39% Loosely correlated | -0.12% | ||
| NVST - FLGT | 38% Loosely correlated | -2.01% | ||
| MXCT - FLGT | 38% Loosely correlated | -2.65% | ||
| CLPT - FLGT | 37% Loosely correlated | +4.56% | ||
More | ||||